1
|
Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF, Adenis A, Alessio A, Aouakli A, Azzedine A, Bedjaoui A, Bidault A, Blanchi A, Botton A, Cadier-Lagnes A, Fatisse A, Gagnaire A, Gilbert A, Gueye A, Hollebecque A, Lemaire A, Mahamat A, Marre A, Patenotte A, Rotenberg A, Roussel A, Thirot-Bidault A, Votte A, Weber A, Zaanan A, Dupont-Gossart A, Villing A, Queuniet A, Coudert B, Denis B, Garcia B, Lafforgue B, Landi B, Leduc B, Linot B, Paillot B, Rhein B, Winkfield B, Barberis C, Becht C, Belletier C, Berger C, Bineau C, Borel C, Brezault C, Buffet C, Cornila C, Couffon C, De La Fouchardière C, Giraud C, Lecaille C, Lepere C, Lobry C, Locher C, Lombard-Bohas C, Paoletti C, Platini C, Rebischung C, Sarda C, Vilain C, Briac-Levaché C, Auby D, Baudet-Klepping D, Bechade D, Besson D, Cleau D, Festin D, Gargot D, Genet D, Goldfain D, Luet D, Malka D, Peré-Vergé D, Pillon D, Sevin-Robiche D, Smith D, Soubrane D, Tougeron D, Zylberait D, Carola E, Cuillerier E, Dorval Danquechin E, Echinard E, Janssen E, Maillard E, Mitry E, Norguet-Monnereau E, Suc E, Terrebonne E, Zrihen E, Pariente E, Almaric F, Audemar F, Bonnetain F, Desseigne F, Dewaele F, Di Fiore F, Ghiringhelli F, Husseini F, Khemissa F, Kikolski F, Morvan F, Petit-Laurent F, Riot F, Subtil F, Zerouala-Boussaha F, Caroli-Bosc F, Boilleau-Jolimoy G, Bordes G, Cavaglione G, Coulanjon G, Deplanque G, Gatineau-Saillant G, Goujon G, Medinger G, Roquin G, Brixi-Benmansour H, Castanie H, Lacroix H, Maechel H, Perrier H, Salloum H, Senellart H, Baumgaertner I, Cumin I, Graber I, Trouilloud I, Boutin J, Butel J, Charneau J, Cretin J, Dauba J, Deguiral J, Egreteau J, Ezenfis J, Forestier J, Goineau J, Lacourt J, Lafon J, Martin J, Meunier J, Moreau J, Provencal J, Taieb J, Thaury J, Tuaillon J, Vergniol J, Villand J, Vincent J, Volet J, Bachet J, Barbare J, Souquet J, Grangé J, Dor J, Paitel J, Jouve J, Raoul J, Cheula J, Gornet J, Sabate J, Vantelon J, Vaillant J, Aucouturier J, Barbieux J, Herr J, Lafargue J, Lagasse J, Latrive J, Plachot J, Ramain J, Robin J, Spano J, Douillard J, Beerblock K, Bouhier-Leporrier K, Slimane Fawzi K, Cany L, Chone L, Dahan L, Gasnault L, Rob L, Stefani L, Wander L, Baconnier M, Ben Abdelghani M, Benchalal M, Blasquez M, Carreiro M, Charbit M, Combe M, Duluc M, Fayolle M, Gignoux M, Giovannini M, Glikmanas M, Mabro M, Mignot M, Mornet M, Mousseau M, Mozer M, Pauwels M, Pelletier M, Porneuf M, Ramdani M, Schnee M, Tissot M, Zawadi M, Clavero-Fabri M, Gouttebel M, Kaminsky M, Galais M, Abdelli N, Barrière N, Bouaria N, Bouarioua N, Delas N, Gérardin N, Hess-Laurens N, Stremsdoerfer N, Berthelet O, Boulat O, Capitain O, Favre O, Amoyal P, Bergerault P, Burtin P, Cassan P, Chatrenet P, Chiappa P, Claudé P, Couzigou P, Feydy P, Follana P, Geoffroy P, Godeau P, Hammel P, Laplaige P, Lehair P, Martin P, Novello P, Pantioni P, Pienkowski P, Pouderoux P, Prost P, Ruszniewski P, Souillac P, Texereau P, Thévenet P, Haineaux P, Benoit R, Coriat R, Lamy R, Mackiewicz R, Beorchia S, Chaussade S, Hiret S, Jacquot S, Lavau Denes S, Montembault S, Nahon S, Nasca S, Nguyen S, Oddou-Lagraniere S, Pesque-Penaud S, Fratte S, Chatellier T, Mansourbakht T, Morin T, Walter T, Boige V, Bourgeois V, Derias V, Guérin-Meyer V, Hautefeuille V, Jestin Le Tallec V, Lorgis V, Quentin V, Sebbagh V, Veuillez V, Adhoute X, Coulaud X, Becouarn Y, Coscas Y, Courouble Y, Le Bricquir Y, Molin Y, Rinaldi Y, Lam Y, Ladhib Z. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. Eur J Cancer 2018; 98:1-9. [DOI: 10.1016/j.ejca.2018.03.031] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2018] [Revised: 03/26/2018] [Accepted: 03/28/2018] [Indexed: 02/07/2023]
|
3
|
Pecout S, Baudin E, Paoli A, Maire F, Terrebonne E, Mitry E, Pavel M, Ruszniewski P, Cadiot G, Brixi-Benmansour H. Efficacy and tolerance of chemotherapy with dacarbazine or temozolomide associated or not with 5-fluorouracil (5-FU) in endocrine carcinomas: A retrospective multicentric study from the Groupe des Tumeurs Endocrines (GTE). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15523 Background: Small studies have shown that therapy with dacarbazine and temozolomide give up to 34% tumoral response rates in endocrine carcinomas. The aim of this large retrospective multicentric study was to evaluate efficacy and tolerance of chemotherapy with dacarbazine or temozolomide associated or not with 5-FU in endocrine carcinomas. Methods: Patients were recruited in 6 French and 1 German centers. All patients with well (WDEC) or poorly-differentiated endocrine carcinoma (PDEC), whatever the primary, and who have been treated with dacarbazine or temozolomide associated or not with iv 5-FU or capecitabine, were included. Response rates were evaluated according to RECIST criteria by one of the investigator and toxicity according to National Cancer Institute Common criteria. Results: 86 patients were included : 36 women, median age 61.7 years (27.7 - 85.7), 67 WHO-PS 0–1. Primaries were : pancreas (n=34), digestive tract (n=23), thyroid (n=9), lung (n=6), other (n=6), unknown (n=8). 64 patients had WDEC and 11 PDEC (11 not determined). The number of previous systemic treatments (chemotherapy, chemoembolization, radionuclide therapy) was: 0 (n=16), 1 (n=25), 2 (n=25), 3 (n=14), 4 and more (n=6). Treatments received were : dacarbazine (n=3), temozolomide (n=19), dacarbazine + 5-FU (n=48), temozolomide + capecitabine (n=16). Evaluation was impossible in two patients. Tumoral response rates (partial and stabilization) were 61.2% in WDEC and 18.2% in PDEC. The best response rates in WDEC were : partial response (n=6; 9.7%), stabilization (n=32; 51.6%), progression (n=24; 38.7%) without significant differences between regimens and primary location. Response rates in WDEC were 88.9%, 71.4% and 64.7% in first, second and third line therapies, respectively. Median progression free survival in WDEC was 5.7 months (0.1–41.7). Grade 3–4 toxicities were hematologic (n=8), digestive (n=10), infection (n=3). Conclusions: Dacarbazine and temozolomide therapy showed high partial response and stabilization rates up to 3rd line therapy in well-differentiated endocrine carcinoma, with moderate toxicity. MGMT tumoral status is currently investigated. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Pecout
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| | - E. Baudin
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| | - A. Paoli
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| | - F. Maire
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| | - E. Terrebonne
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| | - E. Mitry
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| | - M. Pavel
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| | - P. Ruszniewski
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| | - G. Cadiot
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| | - H. Brixi-Benmansour
- CHU Robert Debré, Reims, France; Institut Gustave Roussy, Villejuif, France; Hopital Beaujon, Clichy, France; Hopital Haut Leveque, Bordeaux, France; Hôpital Ambroise Paré, Boulogne Billancourt, France; Charité, Berlin, Germany; Groupe des Tumeurs Endocrines (GTE)
| |
Collapse
|